Literature DB >> 8902575

T-cell recognition of self peptides as tumor rejection antigens.

Y Kawakami1, S A Rosenberg.   

Abstract

Human melanoma antigens and their epitopes recognized by T cells have recently been identified. HLA-A2 binding epitopes of melanoma antigens MART-1 and gp 100 were characterized and suspected to be subdominant/cryptic self determinants. Together with other findings of tumor-specific mutated self peptides as tumor antigens recognized by T cells, the nature of the antitumor immune response to human melanoma has been revealed at a molecular level. These findings have implications not only for understanding of the immune response to self peptides in normal and pathologic conditions, but also for the development of immunotherapies for cancer and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902575     DOI: 10.1007/bf02918248

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  49 in total

Review 1.  Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Int Rev Immunol       Date:  1997       Impact factor: 5.311

Review 2.  Genes coding for tumor antigens recognized by cytolytic T lymphocytes.

Authors:  A Van Pel; P van der Bruggen; P G Coulie; V G Brichard; B Lethé; B van den Eynde; C Uyttenhove; J C Renauld; T Boon
Journal:  Immunol Rev       Date:  1995-06       Impact factor: 12.988

Review 3.  Immunity to oncogenic proteins.

Authors:  M A Cheever; M L Disis; H Bernhard; J R Gralow; S L Hand; E S Huseby; H L Qin; M Takahashi; W Chen
Journal:  Immunol Rev       Date:  1995-06       Impact factor: 12.988

4.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

5.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

6.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

Authors:  P F Robbins; M el-Gamil; Y F Li; S L Topalian; L Rivoltini; K Sakaguchi; E Appella; Y Kawakami; S A Rosenberg
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

7.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.

Authors:  D Arnold; S Faath; H Rammensee; H Schild
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

10.  T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.

Authors:  M Sensi; S Salvi; C Castelli; C Maccalli; A Mazzocchi; R Mortarini; G Nicolini; M Herlyn; G Parmiani; A Anichini
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

Review 2.  Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.

Authors:  Tomonori Yaguchi; Yutaka Kawakami
Journal:  Int Immunol       Date:  2016-07-08       Impact factor: 4.823

Review 3.  Cancer immunotherapy.

Authors:  Thomas F Gajewski
Journal:  Mol Oncol       Date:  2012-01-08       Impact factor: 6.603

4.  CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.

Authors:  R M Kedl; M Jordan; T Potter; J Kappler; P Marrack; S Dow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

5.  Melanoma therapeutics: a literature review.

Authors:  Pavan Kumar Dhanyamraju; Trupti N Patel
Journal:  J Biomed Res       Date:  2022-02-28

6.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors:  R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

Review 7.  Human tumor antigens recognized by T-cells.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1997       Impact factor: 4.505

Review 8.  Cutaneous melanoma and the immunotherapy revolution (Review).

Authors:  Giulia C Leonardi; Saverio Candido; Luca Falzone; Demetrios A Spandidos; Massimo Libra
Journal:  Int J Oncol       Date:  2020-06-25       Impact factor: 5.650

Review 9.  New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy.

Authors:  Nathaniel Oberholtzer; Kristen M Quinn; Paramita Chakraborty; Shikhar Mehrotra
Journal:  Cells       Date:  2022-02-17       Impact factor: 6.600

10.  Melanoma-restricted genes.

Authors:  Ena Wang; Monica C Panelli; Katia Zavaglia; Susanna Mandruzzato; Nan Hu; Phil R Taylor; Barbara Seliger; Paola Zanovello; Ralph S Freedman; Francesco M Marincola
Journal:  J Transl Med       Date:  2004-10-15       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.